Literature DB >> 22607682

Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor.

M Raymond V Finlay1, David Buttar, Susan E Critchlow, Allan P Dishington, Shaun M Fillery, Eric Fisher, Steve C Glossop, Mark A Graham, Trevor Johnson, Gillian M Lamont, Simon Mutton, Paula Perkins, Kurt G Pike, Anthony M Slater.   

Abstract

High throughput screening to identify inhibitors of the mTOR kinase revealed sulfonyl-morpholino-pyrimidine 1 as an attractive start point. The compound displayed good physicochemical properties and selectivity over related kinases such as PI3Kα. Library preparation of related analogs allowed the establishment of additional SAR understanding and in particular the requirement for a key hydrogen bond donor motif at the 4-position of the phenyl ring in compounds such as indole 19. Isosteric replacement of the indole functionality led to the identification of urea compounds such as 32 that show good levels of mTOR inhibition in both enzyme and cellular assays.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22607682     DOI: 10.1016/j.bmcl.2012.04.036

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

Review 1.  Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy.

Authors:  Aamir Ahmad; Bernhard Biersack; Yiwei Li; Dejuan Kong; Bin Bao; Rainer Schobert; Subhash B Padhye; Fazlul H Sarkar
Journal:  Anticancer Agents Med Chem       Date:  2013-09       Impact factor: 2.505

2.  Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines.

Authors:  Sida Shen; Xiangyu He; Zheng Yang; Liang Zhang; Yingtao Liu; Zhiyuan Zhang; Weiwei Wang; Wei Liu; Yufeng Li; Dong Huang; Kai Sun; Xiaojing Ni; Xu Yang; Xinxin Chu; Yumin Cui; Qiang Lv; Jiong Lan; Fusheng Zhou
Journal:  ACS Med Chem Lett       Date:  2018-06-25       Impact factor: 4.345

Review 3.  Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.

Authors:  Mark E Welker; George Kulik
Journal:  Bioorg Med Chem       Date:  2013-05-09       Impact factor: 3.641

4.  Structure-activity relationships study of mTOR kinase inhibition using QSAR and structure-based drug design approaches.

Authors:  Wiame Lakhlili; Abdelaziz Yasri; Azeddine Ibrahimi
Journal:  Onco Targets Ther       Date:  2016-12-02       Impact factor: 4.147

Review 5.  Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.

Authors:  Yu Liu; Wen-Zhu Wan; Yan Li; Guan-Lian Zhou; Xin-Guang Liu
Journal:  Oncotarget       Date:  2017-01-24

Review 6.  Progress towards a clinically-successful ATR inhibitor for cancer therapy.

Authors:  Francis M Barnieh; Paul M Loadman; Robert A Falconer
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-02-05

Review 7.  Overview of Research into mTOR Inhibitors.

Authors:  Beibei Mao; Qi Zhang; Li Ma; Dong-Sheng Zhao; Pan Zhao; Peizheng Yan
Journal:  Molecules       Date:  2022-08-19       Impact factor: 4.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.